Nanobiotix is trying to ride the growing use of radiation therapy in cancer care, while also building a second platform that could help other drugmakers deliver hard-to-target medicines. The big question is whether its major clinical trials and partnership talks deliver real proof and deals—or leave the company spending heavily without a clear payoff.Read more
Nanobiotix is leaning on a big partner to push its lead treatment through major cancer studies, which could speed up progress while the company keeps a slice of future upside. At the same time, its newer delivery platform could open doors in other fast-growing treatment types—but slow trial results or partner priorities could quickly change the story.Read more
Catalysts About Nanobiotix Nanobiotix develops nanoparticle based drug candidates intended to improve the effectiveness of existing cancer treatments such as radiotherapy and complex systemic therapies. What are the underlying business or industry changes driving this perspective?Read more
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
